GGrantIndex
← Leaderboards

Jennifer M. Yeh

Harvard School Of Public Health

$7,047,019
Attributed
$9,600,472
Total exposure
4
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2M · FY201025
$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$9,600,472 · 4

By mechanism

R01$4,794,093 · 2
U01$4,054,972 · 1
K07$751,407 · 1

Top collaborators

Most similar at Harvard School Of Public Health

Same institution · by research overlap

Others in their field

Top investigators on “Malignant Neoplasms

Research focus

Malignant NeoplasmsModels And SimulationHigh RiskRecommendationIncidenceFutureRisk FactorsPreventionMethodologyPrevalenceCancer ControlCessation Of LifeCohort StudiesRaceCaringSubgroupPublishingScreeningClinical ResearchInnovationAdultLesionMalignant Stomach NeoplasmGastric Cancer Prevention

Grant awards (19)

Comparative modeling of gastric cancer health drivers and prevention in the US and globally$899,170
U01 · FY2025 · CA
Can risk-reducing medications improve breast cancer prevention in childhood and adolescent cancer survivors? Comparative modeling to inform care$705,394
R01 · FY2025 · CA · contact PI
Can risk-reducing medications improve breast cancer prevention in childhood and adolescent cancer survivors? Comparative modeling to inform care$621,799
R01 · FY2024 · CA · contact PI
Comparative modeling of gastric cancer disparities and prevention in the US and globally$615,728
U01 · FY2024 · CA
Comparative modeling of gastric cancer disparities and prevention in the US and globally$810,184
U01 · FY2023 · CA
Can risk-reducing medications improve breast cancer prevention in childhood and adolescent cancer survivors? Comparative modeling to inform care$643,968
R01 · FY2023 · CA · contact PI
Comparative modeling of gastric cancer disparities and prevention in the US and globally$810,695
U01 · FY2022 · CA
Can risk-reducing medications improve breast cancer prevention in childhood and adolescent cancer survivors? Comparative modeling to inform care$755,486
R01 · FY2022 · CA · contact PI
Genetic testing to guide pediatric cancer care and follow up: using anthracycline-associated cardiac toxicity as a model for the future$400,065
R01 · FY2022 · CA · contact PI
Comparative modeling of gastric cancer disparities and prevention in the US and globally$919,195
U01 · FY2021 · CA
Genetic testing to guide pediatric cancer care and follow up: using anthracycline-associated cardiac toxicity as a model for the future$400,065
R01 · FY2021 · CA · contact PI
Genetic testing to guide pediatric cancer care and follow up: using anthracycline-associated cardiac toxicity as a model for the future$403,590
R01 · FY2020 · CA · contact PI
Genetic testing to guide pediatric cancer care and follow up: using anthracycline-associated cardiac toxicity as a model for the future$403,427
R01 · FY2019 · CA · contact PI
Genetic testing to guide pediatric cancer care and follow up: using anthracycline-associated cardiac toxicity as a model for the future$460,299
R01 · FY2018 · CA · contact PI
Gastric Cancer Prevention: Evaluating U.S. Risk Factor Trends and New Technology$150,203
K07 · FY2014 · CA · contact PI
Gastric Cancer Prevention: Evaluating U.S. Risk Factor Trends and New Technology$151,002
K07 · FY2013 · CA · contact PI
Gastric Cancer Prevention: Evaluating U.S. Risk Factor Trends and New Technology$151,710
K07 · FY2012 · CA · contact PI
Gastric Cancer Prevention: Evaluating U.S. Risk Factor Trends and New Technology$150,520
K07 · FY2011 · CA · contact PI
Gastric Cancer Prevention: Evaluating U.S. Risk Factor Trends and New Technology$147,972
K07 · FY2010 · CA · contact PI